Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
Glycopeptide
|
---|---|
ln Vitro |
Dalbavancin is a semisynthetic lipoglycopeptide that is injected intravenously and was created to treat illnesses brought on by microorganisms that are resistant to antibiotics. Strong in vitro bactericidal action of dalapavancin is demonstrated against gram-positive bacteria, such as S. MRSA, VISA, and non-VanA strains of VRE aureus. is designed to treat difficult skin and skin structure infections (cSSSIs), mainly caused by β-hemolytic streptococci and MRSA, which it has proven to be more effective against than current glycopeptide therapy agents[1][2].
|
ln Vivo |
Treatment with dalapancin (15–240 mg/kg; intraperitoneal injection; every 36 or 72 hours; for 14 days; female BALB/c mice) results in an 80%–100% survival rate across all dose regimens[1].
|
Animal Protocol |
Animal/Disease Models: Female balb/c (Bagg ALBino) mouse: (6-8 weeks) challenged with Ames strain of B. anthracis[1]
Doses: 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Route of Administration: intraperitoneal (ip)injection; every 36 h or 72 h; for 14 days Experimental Results: The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |
References |
[1]. Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6.
[2]. Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40. |
Molecular Formula |
C88H101CL3N10O28
|
---|---|
Molecular Weight |
1853.15
|
CAS # |
2227366-51-8
|
Related CAS # |
Dalbavancin;171500-79-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
ClC1C=C2C=CC=1OC1=CC3=CC(=C1OC1C(C(C(C(C(=O)O)O1)O)O)NC(CCCCCCCCC(C)C)=O)OC1C=CC(=CC=1)CC1C(NC(C4=C(C(=CC(=C4)OC4C=CC(=CC=4O)C(C(N1)=O)NC)O)Cl)C(NC3C(NC1C(NC(C(NC(C(NCCCN(C)C)=O)C3=CC(=CC(=C3C3=C(C=CC1=C3)O)OC1C(C(C(C(CO)O1)O)O)O)O)=O)C2O)=O)=O)=O)=O.Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 250 mg/mL (134.91 mM)
H2O : 50 mg/mL (26.98 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (1.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.5396 mL | 2.6981 mL | 5.3962 mL | |
5 mM | 0.1079 mL | 0.5396 mL | 1.0792 mL | |
10 mM | 0.0540 mL | 0.2698 mL | 0.5396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.